Abstract:BACKGROUND:Neoadjuvant radiotherapy (RT) has been shown to improve local control; however, whether it can improve overall survival (OS) in locally advanced rectal cancer (LARC) patients remains controversial. We therefore aimed to examine the benefits of surgery alone, neoadjuvant radiotherapy (RT), adjuvant RT, and surgery plus chemotherapy in stage II (T3/4N0M0) and III (any T and N + M0) on the OS of rectal cancer patients. METHODS:Date from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2004 and 2016 were used. Kaplan-Meier analyses were used to compare patient prognoses across different treatment modalities. Cox hazard regression analysis were used to identify independent predictors of OS. RESULTS:For stage T3/4N0M0 patients, neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy resulted in similar OS (all p > 0.05; mean survival, 115.89 months (M), 111.97 M, and 117.22 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival, 88.96 M). For stage T1/2N + M0 patients, neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy resulted in similar OS (all p > 0.05; mean survival, 121.50 M, 124.25 M, and 121.20 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival 83.81 M). For stage T3/4N + M0 patients, neoadjuvant RT (HR = 0.436; 95% CI, 0.396~0.478; p < 0.001) resulted in significantly longer OS than adjuvant RT and surgery plus chemotherapy (mean survival, 104.47 M, 93.94 M, and 93.62 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival 54.87 M). Older age (> 60 years), black race, unmarried status, high tumour grade, and tumour size > 5 cm were all associated with a poor prognosis (all p < 0.05). CONCLUSIONS:Neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy results in better OS than surgery alone in LARC patients. Neoadjuvant RT has the potential to be highly recommended over adjuvant RT and surgery plus chemotherapy for T3/4N + M0 patients; however, it showed no OS advantage over adjuvant RT or surgery plus chemotherapy for T3/4N0M0 and T1/2N + M0 patients.

Does stage III rectal mucinous adenocarcinoma benefit from neoadjuvant chemoradiation?

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Feasibility Of Relatively Low Neoadjuvantradiation Doses For Locally Advanced Rectal Cancer: A Propensity Score-Matched Analysis

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

A Propensity-Score Matched Analysis of the Impact of Neoadjuvant Radiation Therapy on the Outcomes of Stage II-III Mucinous Rectal Carcinoma

Risk stratification of stage II rectal mucinous adenocarcinoma to predict the benefit of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Adjuvant radiotherapy improves cause specific survival in stage II, not stage III mucinous carcinoma of the rectum

Role of Adjuvant Chemotherapy After Curative Resection in Stage II and III Rectal Cancer

Mucinous histology is a negative predictor of neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma

Efficacy of systemic CHEmotherapy on high-risk stage II and III MUcnious Colon CAncer. CHEMUCCA study part I.

Rectal Cancer Survival for Residual Carcinoma In Situ Vs. Pathologic Complete Response After Neoadjuvant Therapy

Survival Comparison of Stage IIA Rectal Cancer with or Without Neoadjuvant Therapy: a SEER Database Analysis with Propensity Score Matching

A Clinical Study to Evaluate the Toxicities of Adjuvant Chemoradiotherapy in Early Stage after Low-Anterior Resection for Locally Advanced Rectal Cancer

MRI-defined High-Risk Rectal Cancer Patients: Outcome Comparison Between Neoadjuvant Chemoradiotherapy Plus TME and TME Plus Adjuvant Chemotherapy or TME Alone

Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study

MRI‐defined T3, clear mesorectal fascia mid–low rectal cancer: is neoadjuvant treatment necessary?

Neoadjuvant Therapy for Advanced Rectal Carcinoma in China: Whether Radiochemotherapy is Superior to Radiotherapy?

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study

Effects of neoadjuvant chemotherapy with or without intensity‐modulated radiotherapy for patients with rectal cancer

CMISG1701: a Multicenter Prospective Randomized Phase III Clinical Trial Comparing Neoadjuvant Chemoradiotherapy to Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy in Patients with Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (Ct3-4An0-1m0) (NCT03001596)